IQV in “GLP-1 Eats Everything”
IQVIA Holdings Inc.
IQVIA benefits from the large number of obesity, combination-therapy, and cardiometabolic clinical trials requiring outsourced research and data services.
IQV impact map — “GLP-1 Eats Everything”
How this story travels from the headline to IQV’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading IQV impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 252 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — IQVIA benefits from the large number of obesity, combination-therapy, and cardiometabolic clinical trials requiring outsourced research and data services.
Read the full GLP-1 Eats Everything storyBull side
1 story- Viewing
IQV in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
IQVIA benefits from the large number of obesity, combination-therapy, and cardiometabolic clinical trials requiring outsourced research and data services.
Bear side
1 story- China Becomes Pharma's Global R&D Engine
IQV in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Sponsors sourcing more development work through Chinese networks can constrain growth in higher-cost traditional trial services.